ABSTRACT
BM 12.531, 2-[2-cyranaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane, a new immunostimulant compound, increased the resistance of mice to infection with Candida albicans. Because BM 12.531 had no fungistatic activity in vitro, it is proposed that the therapeutic effect of BM 12.531 is caused by the stimulation of cell-mediated immunity. Administration of cyclophosphamide alone increased the mortality among mice infected with C. albicans and Pseudomonas aeruginosa, but when BM 12.531 was then administered to these animals, the mortality was reduced. Among mice with acute Escherichia coli infection, a synergistic effect of chloramphenicol and BM 12.531 was demonstrated.
Subject(s)
Aziridines/immunology , Azirines/immunology , Immunity, Cellular/drug effects , Animals , Candidiasis/immunology , Chloramphenicol/therapeutic use , Cyclophosphamide/therapeutic use , Drug Evaluation, Preclinical , Drug Synergism , Drug Therapy, Combination , Escherichia coli Infections/immunology , Female , In Vitro Techniques , Mice , Mice, Inbred Strains , Microbial Sensitivity Tests , Pseudomonas Infections/immunology , Stimulation, ChemicalABSTRACT
Tests conducted on mice of the CBA line immunized with sheep erythrocytes have brought evidence that, when introduced to the animals 24 and 48 hours after immunization, phosphemide appreciably reduces the number of cells producing the IgM- and IgG-anibodies. The maximum immunodepressive effect of phopurine was observed when this was introduced simultaneously with the antigen, and also 24 and 48 hours following immunization. Both compounds produced a change in the mass of the immuno-competent organs and reduced the number of nuclei-containing cells in the spleen throughout the entire period of investigation.
